TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BeiGene Ltd ( (HK:6160) ) just unveiled an update.
BeOne Medicines Ltd., a company incorporated under Swiss law, has announced the granting of share options, restricted share units (RSUs), and performance share units (PSUs) under its 2016 Share Option and Incentive Plan. The grants include options for 147,355 American Depositary Shares (ADSs) to 31 grantees, RSUs for 1,720,092 ADSs to 9,012 grantees, and PSUs for 141,377 ADSs to 30 grantees. This move is part of the company’s strategy to incentivize and retain talent, aligning employee interests with shareholder value. The options have a ten-year validity, with a structured vesting schedule and a clawback mechanism to ensure compliance with company policies.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,657,581
Technical Sentiment Signal: Buy
Current Market Cap: HK$257.5B
For detailed information about 6160 stock, go to TipRanks’ Stock Analysis page.